Motley Fool Money

DTC Healthcare with 23andMe CEO Anne Wojcicki

Apr 24, 2022

Anne Wojcicki, CEO of 23andMe, dives into the transformative impact of direct-to-consumer genetic testing on healthcare. She explains how understanding our genes can lead to more personalized medicine and discusses the gaps in integrating genetic insights into primary care. The conversation touches on the company’s strategic move to acquire Lemonade Health for enhancing healthcare solutions. Additionally, Wojcicki reveals how genetic data is reshaping drug development and what the future holds for 23andMe in this evolving landscape.

26:13

Creator website

Episode guests

Anne Wojcicki

AI Chapters

Episode notes

Intro

2min

Unlocking Genetic Insights: The 23andMe Journey

14min

Enhancing Personalized Healthcare Through Strategic Acquisition

5min

Innovations in Drug Development Through Genetic Insights

3min

Analyzing the Future of 23andMe: Innovation and Data Assets

2min

Genes aren’t always predictive, but understanding them better could dramatically improve our healthcare system. Motley Fool contributor Brian Orelli interviews Anne Wojcicki, the CEO of 23andMe, about her company and why it’s looking to tell you much more than the names of your long-lost relatives. They discuss: - Opportunities in direct-to-consumer healthcare - Creating more personalized medicine - The limits of genetic testing

Host: Brian Orelli Guest: Anne Wojcicki Producer: Ricky Mulvey Engineers: Dan Boyd, Brandon Gentry

Learn more about your ad choices. Visit megaphone.fm/adchoices

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.